Unknown

Dataset Information

0

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.


ABSTRACT: Neuroendocrine tumors (NETs) are grouped together as a single class on the basis of histologic appearance, immunoreactivity for the neuroendocrine markers chromogranin A and synaptophysin, and potential secretion of hormones, neurotransmitters, neuromodulators and neuropeptides. Nevertheless, despite these common characteristics, NETs differ widely in terms of their natural histories: high-grade NETs are clinically aggressive and, like small cell lung cancer, which they most closely resemble, tend to respond to cisplatin and etoposide. In contrast, low-grade NETs, which as a rule progress and behave indolently, do not. In either case, the treatment strategy, apart from potentially curative surgical resection, is very poorly defined. This report describes the case of a 28-year-old white male with a diagnosis of high-grade NET of undetermined primary site metastatic to the lymph nodes, skin and paraspinal soft tissues, treated with the experimental anticancer agent RRx-001, in the context of a phase II clinical trial called TRIPLE THREAT (NCT02489903); serial sampling of tumor material through repeat biopsies demonstrated an intratumoral inflammatory response, including the amplification of infiltrating T cells, which correlated with clinical and symptomatic benefit. This case suggests that pseudoprogression or RRx-001-induced enlargement of tumor lesions, which has been previously described for several RRx-001-treated patients, is the result of tumoral lymphocyte infiltration.

SUBMITTER: Carter CA 

PROVIDER: S-EPMC4821155 | biostudies-literature | 2016 Jan-Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Carter Corey A CA   Schmitz Bruno B   Peterson P Gabriel PG   Quinn Mary M   Degesys Aiste A   Jenkins John J   Oronsky Bryan B   Scicinski Jan J   Caroen Scott S   Reid Tony R TR   Cabrales Pedro P   Brzezniak Christina C  

Case reports in oncology 20160101 1


Neuroendocrine tumors (NETs) are grouped together as a single class on the basis of histologic appearance, immunoreactivity for the neuroendocrine markers chromogranin A and synaptophysin, and potential secretion of hormones, neurotransmitters, neuromodulators and neuropeptides. Nevertheless, despite these common characteristics, NETs differ widely in terms of their natural histories: high-grade NETs are clinically aggressive and, like small cell lung cancer, which they most closely resemble, te  ...[more]

Similar Datasets

| S-EPMC4649750 | biostudies-literature
| S-EPMC4673285 | biostudies-literature
| S-EPMC5270305 | biostudies-literature
| S-EPMC5093055 | biostudies-literature
| S-EPMC4791224 | biostudies-literature
2016-12-31 | GSE74797 | GEO
| S-EPMC6293266 | biostudies-literature
| S-EPMC5731976 | biostudies-literature
| S-EPMC10277641 | biostudies-literature
| S-EPMC6847805 | biostudies-literature